Patents by Inventor Arthur M. Friedlander

Arthur M. Friedlander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786601
    Abstract: A pegylated, circularly permuted construct of the CapD enzyme (a gamma glutamyl transferase enzyme acting as a hydrolase specific to poly-?-D-glutamic acid) is used to treat anthrax and other bacterial infections, including but not limited to infection with strains that are resistant to available antibiotics.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: October 17, 2023
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Patricia M. Legler, Arthur M. Friedlander, Jaimee R. Compton
  • Publication number: 20220233703
    Abstract: A pegylated, circularly permuted construct of the CapD enzyme (a gamma glutamyl transferase enzyme acting as a hydrolase specific to poly-?-D-glutamic acid) is used to treat anthrax and other bacterial infections, including but not limited to infection with strains that are resistant to available antibiotics.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 28, 2022
    Inventors: Patricia M. Legler, Arthur M. Friedlander, Jaimee R. Compton
  • Patent number: 8795677
    Abstract: Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis to the subject.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: August 5, 2014
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David G. Heath, Arthur M. Friedlander, George W. Anderson, Jr., Susan L. Welkos
  • Patent number: 8647633
    Abstract: Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis that is isolated from its expression vector.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: February 11, 2014
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: David G. Heath, Arthur M. Friedlander, George W. Anderson, Jr., Susan L. Welkos
  • Publication number: 20120164156
    Abstract: Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis to the subject.
    Type: Application
    Filed: May 6, 2008
    Publication date: June 28, 2012
    Inventors: David G. Heath, Arthur M. Friedlander, George W. Anderson, JR., Susan L. Welkos
  • Publication number: 20100226906
    Abstract: In this application is described isolated, recombinant CapD and recombinant PghP for use in digesting capsule comprising polyglutamate polymers and for treatment of infections caused by bacilli having a polyglutamate capsule, such as anthrax.
    Type: Application
    Filed: September 19, 2006
    Publication date: September 9, 2010
    Inventors: Arthur M. Friedlander, Angelo Scorpio, Donald J. Chabot
  • Publication number: 20090022756
    Abstract: Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis that is isolated from its expression vector.
    Type: Application
    Filed: May 6, 2008
    Publication date: January 22, 2009
    Inventors: David G. Heath, Arthur M. Friedlander, George W. Anderson, JR., Susan L. Welkos
  • Publication number: 20070043215
    Abstract: A recombinant vaccine is described which is composed of one recombinant protein comprising F1 and V antigen of Yersinia pestis. This vaccine protects experimental mice against pneumonic as well as bubonic plague produced by either F1+ or F1? strains of Y. pestis and may provide the basis for an improved human plague vaccine.
    Type: Application
    Filed: August 27, 1996
    Publication date: February 22, 2007
    Inventors: DAVID G. HEATH, ARTHUR M. FRIEDLANDER, GEORGE W. ANDERSON, SUSAN L. WELKOS
  • Patent number: 6387665
    Abstract: A method of making a vaccine for anthracis that inolves a bacterial expression system and production and use of protective antigen (PA) against Bacillus anthracis. The PA immunogen is useful in a vaccine against human anthrax. The PA can be produced by an asporogenic organism which produces the desired antigen, which is then harvested from the supernatant.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: May 14, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Bruce Ivins, Patricia Worsham, Arthur M. Friedlander, Joseph W. Farchaus, Susan L. Welkos
  • Publication number: 20020034512
    Abstract: A method of making a vaccine from a protective antigen. The protective antigen is useful against Bacillus anthracis. The protective antigenis produced by an asporogenic organism which overpoduces the desired antigen. The asporogenic organism is a recombinant asporogenic B. anthracis. The recombinant asporogenic B. anthracis was derived from a &Dgr;Sterne-1(pPA102) strain of bacteria and binds to dye when grown on Congo Red Agar.
    Type: Application
    Filed: March 7, 2000
    Publication date: March 21, 2002
    Inventors: Bruce Ivins, Patricia Worsham, Arthur M Friedlander, Joseph W Farchaus, Susan L Welkos
  • Patent number: 6316006
    Abstract: This invention relates to a bacterial expression system for production of protective antigen (PA) against bacillus anthracis. Recombinant asporogenic B. anthracits that are derived from &Dgr;Sterne-1(pPA102) and show inability to bind the dye when grown on Congo Red Agar can be screened and asporogenic strains isolated using methods of the invention. organisms of the invention lacking spore-forming function may be killed by heat shock at temperatures as low as 60° C. for 60 minutes. Hence, contamination of the environment with viable spore-forming organisms is easily avoided and decontamination is easily accomplished.
    Type: Grant
    Filed: November 23, 1994
    Date of Patent: November 13, 2001
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Patricia Worsham, Arthur M. Friedlander, Bruce Ivins